{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "Covid-19",
      "Pharmacological treatments",
      "Renin-angiotensin system",
      "Sistema renina-angiotensina",
      "Tratamientos farmacol\u00f3gicos"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33877122",
  "DateCompleted": {
    "Year": "2021",
    "Month": "04",
    "Day": "26"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.24875/GMM.M21000459"
    ],
    "Journal": {
      "ISSN": "0016-3813",
      "JournalIssue": {
        "Volume": "156",
        "Issue": "6",
        "PubDate": {
          "Year": "2020"
        }
      },
      "Title": "Gaceta medica de Mexico",
      "ISOAbbreviation": "Gac Med Mex"
    },
    "ArticleTitle": "COVID-19: a basic approach to understanding potential treatments.",
    "Pagination": {
      "StartPage": "570",
      "EndPage": "575",
      "MedlinePgn": "570-575"
    },
    "Abstract": {
      "AbstractText": [
        "SARS-CoV-2 virus has been identified as the causative agent of the COVID-19 pandemic. Even when no standard treatment is available, antivirals such as remdesivir and other drugs such as chloroquine and ivermectin, which interfere with viral replication, have been assayed. Some strategies aimed at reducing immune mechanisms, such as the use of tocilizumab and natural antioxidants, have also been tested. The use of drugs related to the renin-angiotensin system has been controversial. Pathogenicity mechanisms, as well as controlled treatments, still have to be studied in detail in order to propose a viable therapeutic option that prevents the entry and replication of the virus or enhances the host immune system. El virus SARS-CoV-2 ha sido identificado como el agente patol\u00f3gico causante de la pandemia de COVID-19. Aun cuando no se cuenta con un tratamiento est\u00e1ndar, se han probado antivirales como remdesivir y otros f\u00e1rmacos como cloroquina e ivermectina, que interfieren con la replicaci\u00f3n del virus. Tambi\u00e9n se han intentado algunas estrategias encaminadas a disminuir los mecanismos inmunitarios, como el uso de tocilizumab y antioxidantes naturales. Los f\u00e1rmacos relacionados con el sistema renina-angiotensina han resultado controversiales. A\u00fan se debe estudiar con detalle los mecanismos de patogenicidad, as\u00ed como los tratamientos controlados para proponer alguna opci\u00f3n terap\u00e9utica viable que evite la entrada y replicaci\u00f3n del virus o que aumente los sistemas inmunitarios del hu\u00e9sped."
      ],
      "CopyrightInformation": "Copyright: \u00a9 2020 Permanyer."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Research Section, Escuela Militar de Medicina, Secretar\u00eda de la Defensa Nacional, Mexico City."
          }
        ],
        "LastName": "Cedillo-Alvarez",
        "ForeName": "Carla",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Biomedical Research Unit, Iztacala Faculty of Higher Studies, Universidad Nacional Aut\u00f3noma de M\u00e9xico, State of Mexico."
          }
        ],
        "LastName": "Gallardo-Ortiz",
        "ForeName": "Itzell A",
        "Initials": "IA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Neurochemistry Department, Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda, Mexico City."
          }
        ],
        "LastName": "L\u00f3pez",
        "ForeName": "Luis T",
        "Initials": "LT"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Neurochemistry Department, Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda, Mexico City."
          }
        ],
        "LastName": "Montes",
        "ForeName": "Sergio",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Post-degree and Research Section, Higher School of Medicine, Instituto Polit\u00e9cnico Nacional, Mexico City. Mexico."
          }
        ],
        "LastName": "P\u00e1ez-Mart\u00ednez",
        "ForeName": "Nayeli",
        "Initials": "N"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ],
    "VernacularTitle": "COVID-19: enfoque b\u00e1sico para entender sus tratamientos."
  },
  "MedlineJournalInfo": {
    "Country": "Mexico",
    "MedlineTA": "Gac Med Mex",
    "NlmUniqueID": "0010333",
    "ISSNLinking": "0016-3813"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "pharmacology"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug effects",
        "isolation & purification"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Virus Internalization"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Virus Replication"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ]
}